Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Johnson & Johnson (NYSE: JNJ) is slowly starting to breathe again — without fear of asbestos.

Johnson & Johnson Says Independent Labs Found No Asbestos In Recalled Powder

Ever since Johnson & Johnson  disclosed this month that a government test had turned up asbestos in its Baby Powder, the company has attacked the validity of the result.

Exclusive: J&J's own expert, working for FDA, found asbestos in Baby Powder

GlaxoSmithKline

Which stock is the better pick between these two healthcare giants?

Better Buy: Johnson & Johnson vs. GlaxoSmithKline

Shares of Johnson & Johnson popped in below-average volume after the close on Tuesday after the health company said new tests found no traces of asbestos in its baby powder.
The post JNJ Stock Pops After New Testing Finds No Asbestos In Baby Powder appeared first on Investor's Business Daily.

JNJ Stock Pops After New Testing Finds No Asbestos In Baby Powder

Johnson & Johnson  said on Tuesday that 15 new tests from the same bottle of its baby powder previously tested by the U.S. Food and Drug Administration found no asbestos.

Johnson & Johnson says new tests find no asbestos in FDA-tested baby powder

Johnson & Johnson says it retested its Johnson’s Baby Powder and found no signs of asbestos that prompted the recall.

Johnson & Johnson says it found no signs of asbestos in baby powder after testing

Johnson & Johnson (NYSE: JNJ) generates its revenues from sales of pharmaceutical products, medical devices, and consumer products. The company’s revenues have grown 14% between 2016 and 2018, led by Actelion and Abbott Medical Optics acquisitions, and growth in some of its oncology drugs.

Could Johnson & Johnson’s Revenue Growth Stall?

Johnson & Johnson received grand jury subpoenas in August from the U.S. attorney's office for the Eastern District of New York related to its opioid medication policies, the company said in a regulatory filing on Monday.

Justice Department issues grand jury subpoenas in J&J opioid probe: filing

Just as Johnson and Johnson was working to put aside its legal troubles, a fresh asbestos controversy occurred. Still, the case for JNJ stock isn’t as terrible as you might think due to society’s willingness to forget scandals over time.

Can Johnson and Johnson Survive this Latest Controversy?

J&J is a well-diversified company that has delivered strong financial results over the years.

Johnson & Johnson: The Inconsistent Matter Of Management, The Credo, And The Talc Problem

CVS Health

Rite Aid

Walmart

Walmart, CVS and Rite Aid have pulled some or all 22-ounce bottles of Johnson’s baby powder from shelves to avoid confusing consumers, after a minuscule amount of asbestos was found in one bottle. Johnson & Johnson recalled all 33,000 bottles from the same lot as that bottle last Friday, a day after the US Food.

Retailers pull Johnson’s baby powder after recall

Target

Four major U.S. retailers, including Walmart and Target Corp, are removing all 22-ounce bottles of Johnson & Johnson's baby powder from their stores, following the healthcare conglomerate's recall last week of some bottles due to possible asbestos contamination.

Big U.S. retailers pull 22-ounce J&J baby powder off shelves after recall

Boeing

The market seems to be giving JNJ stock a pass while hitting Boeing stock hard. It should be doing the opposite.

Investors Should Short JNJ Stock and Buy Boeing Stock

Walmart Inc has removed and blocked sales of Johnson & Johnson's 22-ounce baby powder bottles from its stores, CNBC reported on Thursday, making it the third large retailer to pull the product.

Walmart pulls 22-ounce J&J baby powder from shelves - CNBC

CVS Health Corp and Rite Aid Corp are removing all 22-ounce bottles of Johnson & Johnson's baby powder from their stores, following the healthcare conglomerate's recall last week of some bottles due to possible asbestos contamination.

CVS, Rite Aid pull all 22-ounce J&J baby powder from stores

CVS Pharmacy is pulling all containers of Johnson & Johnson's 22-ounce baby powder after the FDA found sub-trace levels of asbestos, the pharmacy chain announced Thursday.

CVS pulls all J&J 22 ounce baby powder from shelves after FDA finds sub-trace levels of asbestos

Johnson & Johnson on Wednesday lowered its previously reported third-quarter profit by $3 billion to account for a proposed opioid settlement payment.

J&J slashes third-quarter profit by $3 billion over proposed opioid deal

Johnson & Johnson Inc. JNJ, +0.54% said it lowered its September-ending earnings to account for opioid litigation, according to a Securities and Exchange Commission filing late Wednesday.

Johnson & Johnson restates earnings over opioid settlement

Johnson & Johnson  on Wednesday lowered its previously reported profit for the third quarter to $1.8 billion from $4.8 billion to account for a proposed opioid settlement payment.

Johnson & Johnson says proposed opioid settlement to lower reported third-quarter profit by $3 billion

Teva Pharmaceutical

Walgreens

Don’t play the headlines and don’t make the mistake of lumping all opioid stocks together.

2 Sells and 1 Buy in Opioid Stocks

A previously-unreported deposition could complicate other ongoing litigation.

Report: Johnson & Johnson CEO ‘Believed’ Baby Powder Was Asbestos-Free 13 Days Before FDA Found Trace Levels

JNJ stock while largely flat in terms of performance for the year-to-date has dropped nearly 10% over the past few trading days, bringing it to a well-defined support area. This, coupled with a still attractive dividend yield should get the bulls' attention.

Trade of the Day: Johnson and Johnson Stock’s Dip Is Signal for the Bulls

Facing off against a plaintiff’s lawyer for the first time about Johnson & Johnson’s Baby Powder, the company’s Chief Executive Alex Gorsky earlier this month insisted that the company’s iconic brand was safe.

Johnson & Johnson CEO testified Baby Powder was safe 13 days before FDA bombshell

Johnson & Johnson hasn't been priced at "Fair" or below "Fair" value of P/E 15 since 2013.

Why You Must Look At Fairly-Valued Johnson & Johnson

Even an earnings beat wasn't enough to give the company's share price a big boost.

News for Johnson & Johnson Stock (JNJ)